"25% OFF Western Blot Antibodies with code "MEMORIAL25" Valid 5/23/24-6/1/24 - for US customers and direct orders only"

PANK2 Polyclonal Antibody, AbBy Fluor® 680 Conjugated

Applications

  • WB
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Mouse

Predicted Reactivity

  • Human
  • Rat
  • Dog
  • Cow
  • Pig
  • Horse
Overview
Catalog # bs-8338R-BF680
Product Name PANK2 Polyclonal Antibody, AbBy Fluor® 680 Conjugated
Applications WB, IF(IHC-P), IF(IHC-F), IF(ICC)
Reactivity Mouse
Predicted Reactivity Human, Rat, Dog, Cow, Pig, Horse
Specifications
Conjugation AbBy Fluor® 680
Host Rabbit
Source KLH conjugated synthetic peptide derived from human PANK2
Immunogen Range 401-500/570
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 80025
Swiss Prot Q9BZ23
Subcellular location Cytoplasm
Synonyms Pantothenate kinase 2, mitochondrial; hPanK2; Pantothenic acid kinase 2; PANK2; C20orf48; PANK2_HUMAN
Background Defects in PANK2 are the cause of neurodegeneration with brain iron accumulation type 1 (NBIA1); also known as pantothenate kinase-associated neurodegeneration (PKAN) or Hallervorden-Spatz syndrome (HSS). It is an autosomal recessive neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. Clinical manifestations include progressive muscle spasticity, hyperreflexia, muscle rigidity, dystonia, dysarthria, and intellectual deterioration which progresses to severe dementia over several years. It is clinically classified into classic, atypical, and intermediate phenotypes. Classic forms present with onset in the first decade, rapid progression, loss of independent ambulation within 15 years. Atypical forms have onset in the second decade, slow progression, maintenance of independent ambulation up to 40 years later. Intermediate forms manifest onset in the first decade with slow progression or onset in the second decade with rapid progression. Patients with early onset tend to also develop pigmentary retinopathy, whereas those with later onset tend to also have speech disorders and psychiatric features. All patients have the 'eye of the tiger' sign on brain MRI.Defects in PANK2 are the cause of hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP). HARP is a rare syndrome with many clinical similarities to NBIA1.
Application Dilution
WB 1:300-5000
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200